Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on
H. pylori
Helicobacter pylori
Hp-EuReg
bismuth
culture
eradication failure
rescue
rifabutin
treatment
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Mar 2022
16 Mar 2022
Historique:
received:
17
02
2022
revised:
07
03
2022
accepted:
11
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
First-line International multicentre prospective non-interventional European Registry on Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation. Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of
Sections du résumé
BACKGROUND
BACKGROUND
First-line
METHODS
METHODS
International multicentre prospective non-interventional European Registry on
RESULTS
RESULTS
Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation.
CONCLUSION
CONCLUSIONS
Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of
Identifiants
pubmed: 35329984
pii: jcm11061658
doi: 10.3390/jcm11061658
pmc: PMC8949410
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gastroenterol Hepatol. 2021 Oct 7;:
pubmed: 34629204
Helicobacter. 2016 Oct;21(5):375-81
pubmed: 26807668
Lancet. 1996 Sep 7;348(9028):685
pubmed: 8782773
Am J Gastroenterol. 2000 Mar;95(3):833-4
pubmed: 10710100
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1469-74
pubmed: 17032282
Antibiotics (Basel). 2020 Oct 09;9(10):
pubmed: 33050205
Clin Gastroenterol Hepatol. 2013 May;11(5):507-10
pubmed: 23267869
Aliment Pharmacol Ther. 2012 Apr;35(8):941-7
pubmed: 22372560
Therap Adv Gastroenterol. 2020 Nov 12;13:1756284820968736
pubmed: 33240392
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Gut. 2021 Jan;70(1):40-54
pubmed: 32958544
Eur J Intern Med. 2020 Nov;81:50-53
pubmed: 32646659
BMC Gastroenterol. 2007 Jul 25;7:31
pubmed: 17651479
Aliment Pharmacol Ther. 2005 Jan 1;21(1):91-6
pubmed: 15644050
Dig Liver Dis. 2005 Jan;37(1):33-8
pubmed: 15702857
Gastroenterol Res Pract. 2015;2015:415648
pubmed: 26106411
J Gastrointestin Liver Dis. 2014 Dec;23(4):367-70
pubmed: 25531993
Helicobacter. 2013 Oct;18(5):373-7
pubmed: 23581720
Helicobacter. 2019 Feb;24(1):e12554
pubmed: 30440097
J Clin Gastroenterol. 2018 Feb;52(2):137-140
pubmed: 27136964
Gastroenterology. 2016 Jul;151(1):51-69.e14
pubmed: 27102658
Aliment Pharmacol Ther. 2001 Jan;15(1):143
pubmed: 11136288
Aliment Pharmacol Ther. 2012 Dec;36(11-12):1076-83
pubmed: 23072648
Aliment Pharmacol Ther. 2003 Feb 15;17(4):553-60
pubmed: 12622764
Gastroenterology. 2018 Nov;155(5):1372-1382.e17
pubmed: 29990487
J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14
pubmed: 21188333
J Clin Gastroenterol. 2000 Oct;31(3):222-5
pubmed: 11034001
Pathogens. 2020 Dec 28;10(1):
pubmed: 33379336
Gut. 2021 Oct;70(10):1815-1822
pubmed: 33837118
Am J Gastroenterol. 2017 Feb;112(2):212-239
pubmed: 28071659
Helicobacter. 2019 Oct;24(5):e12630
pubmed: 31282060
Nat Rev Gastroenterol Hepatol. 2010 Oct;7(10):538-9
pubmed: 20890314
Aliment Pharmacol Ther. 2012 Jan;35(2):209-21
pubmed: 22129228
N Engl J Med. 2019 Mar 21;380(12):1158-1165
pubmed: 30893536
Gut. 2013 Jan;62(1):34-42
pubmed: 22580412
Clin Infect Dis. 1995 Sep;21(3):594-8
pubmed: 8527549
United European Gastroenterol J. 2016 Jun;4(3):380-7
pubmed: 27403304
Aliment Pharmacol Ther. 2006 Jul 15;24(2):395-403
pubmed: 16842467
Drugs. 2004;64(17):1893-904
pubmed: 15329036
Aliment Pharmacol Ther. 2011 Sep;34(6):604-17
pubmed: 21745241
Eur J Clin Pharmacol. 2009 Jan;65(1):19-31
pubmed: 18925391
Aliment Pharmacol Ther. 2006 Feb 15;23(4):481-8
pubmed: 16441468
Aliment Pharmacol Ther. 2000 Mar;14(3):311-6
pubmed: 10735924
Antimicrob Agents Chemother. 1999 Jun;43(6):1497-9
pubmed: 10348780
Am J Gastroenterol. 2021 Jun 1;116(6):1220-1229
pubmed: 33840725
Aliment Pharmacol Ther. 2006 Jan 1;23(1):35-44
pubmed: 16393278
BMC Gastroenterol. 2001;1:7
pubmed: 11545677
Gut. 2017 Jan;66(1):6-30
pubmed: 27707777
J Gastroenterol Hepatol. 2021 Jun;36(6):1392-1402
pubmed: 33037845
Ann Intern Med. 2020 Jun 16;172(12):795-802
pubmed: 32365359
Helicobacter. 2008 Feb;13(1):69-74
pubmed: 18205669
Am J Gastroenterol. 2001 Jan;96(1):58-62
pubmed: 11197288
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1537-42
pubmed: 17903237